Syngene International reported a consolidated profit of ₹150 million for Q3 ended December 31, 2025, a sharp decrease from the ₹1.31 billion reported in the same quarter last year. Total income increased to ₹9.32 billion. The company’s board has approved these unaudited financial results. The company opted for “Vivad se Vishwas Scheme, 2024” that resulted in settlement of pending TDS.
Financial Performance Overview
Syngene International announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company’s consolidated profit for Q3 stood at ₹150 million, significantly lower than the ₹1.31 billion reported for Q3 of the previous year. The total income for the quarter increased to ₹9.32 billion, compared to ₹9.62 billion in the corresponding quarter of the previous year.
Standalone Financial Highlights
On a standalone basis, the company’s profit for Q3 2025 was ₹165 million compared to ₹1.23 billion in Q3 2024. The standalone total income was ₹8.49 billion compared to ₹8.95 billion in the previous year.
Key Expenses
The company’s expenses included cost of chemicals, reagents and consumables consumed at ₹2.21 billion. Employee benefits expense reached ₹2.67 billion. Depreciation and amortisation expense amounted to ₹1.14 billion.
Taxation
The current tax for the quarter was ₹109 million, and deferred tax stood at ₹25 million.
Operational Update
Syngene USA Inc. acquired a biologics site in the USA, fitted with multiple monoclonal antibody (mAbs) manufacturing lines. As of December 31, 2025, additional pre-operating cost of Rs. 304 million eligible for capitalisation has been accumulated under capital work in progress.
Other Key Points
The company opted for “Vivad se Vishwas Scheme, 2024” that resulted in settlement of pending TDS assessments related to non resident tax deductions.
On April 23, 2025, the Board of Directors approved an allotment of equity shares to Syngene Employees Welfare Trust.
The Board of Directors recommended a final dividend of ₹1.25 per equity share on April 23, 2025.
Source: BSE
